Navigation Links
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Date:4/29/2008

, for 240 days. Baseline, periodic and terminal measurements of renal enzymes and proteinuria (presence of proteins in the urine associated with kidney malfunctions), blood urea nitrogen, and other tests were done on all subjects in the treatment and control groups.

At the completion of the study, only 2 of the 29 mice in the 40 mg/kg group had elevated proteinuria compared to 21 of the 30 mice in the control group. All 29 (100%) of the mice treated with 40 mg/kg of R788 survived the duration of the study, compared to 14 of the 30 (47%) mice in the control group. The mice treated with 10 mg/kg and 20 mg/kg of R788 demonstrated results that were between those of the control group and the 40 mg/kg group. In a separate study, where treatment was initiated after the onset of disease, the researchers noted that the majority of the animals (~95%) given the 40 mg/kg dose had elevated proteinuria levels that decreased following the onset drug treatment.

Systemic Lupus Erythematosus (SLE)

Lupus is an autoimmune disease, which affects nearly 2 million Americans, the majority of whom are women (90%). The disease affects various parts of the body including the kidneys, skin, joints, heart, lungs, and brain. Its effects can be mild, limited to a couple of organs in the body and occasional flare-ups, or can cause serious and life-threatening complications. Like other autoimmune diseases the primary characteristic of lupus is inflammation, which causes swelling, pain, loss of function and may ultimately destroy the involved organ if left untreated. Current therapies for lupus treat the symptoms of the disease and include non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, and, in severe cases where organ damage is at risk, immunosuppressant drugs.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drug
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
3. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
9. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
10. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
11. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
(Date:9/2/2014)... 2, 2014  Reportlinker.com announces that a new market ... Chinese and Taiwanese Markets for Minimally Invasive Spinal ... The market for MIS spinal devices in ... is growing at a fast pace, albeit at different ... happening in China , where MIS ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the ... filed a lawsuit in Iowa ... law that restricts tools used by PBMs ... and consumers.  The law—HF 2297—forces PBMs ... use of Maximum Allowable Cost (MAC) lists that keep ...
Breaking Medicine Technology:FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
... Editor-in-Chief of New Brain Stimulation Journal, CHARLESTON, ... (MUSC) today announced the results of a functional ... Nerve Stimulation) Therapy(TM),for patients with treatment-resistant depression (TRD). ... MUSC Department of Psychiatry,appears in the August 2007 ...
Cached Medicine Technology:Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 2New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 3
(Date:9/2/2014)... 2014 Becker's Healthcare is excited ... Program on October 23-25, 2014 at the Swissotel ... - The Business and Operations of ASCs brings ... continuing education, networking events, and an exhibit hall ... Outstanding educational offerings throughout the three-day event, The ...
(Date:9/2/2014)... BOSTON (September 2, 2014 4 pm EDT): In a ... American Medical Association , a team of Boston researchers ... improve dietary quality in the United States. The researchers ... at Tufts University, Harvard University and Boston Children,s Hospital ... subsidizing healthier foods could both help people make meaningful ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... by radiation therapy survived as long as patients ... study conducted by researchers at the Stanford University ... of California. , The comprehensive analysis of nearly ... first to directly compare survival rates following the ... removal of both breasts), unilateral mastectomy (the removal ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... Nov. 25 Thanksgiving meals will be delivered to approximately ... to Faith In Action/Volunteer Action for Aging, a program operated ... Plan. For more than 17 years these organizations have gathered ... in need in Long Beach, Lakewood, Signal Hill, South Bay, ...
... LOS ANGELES, Nov. 25 The Black AIDS Institute recently ... 2010. , The new Board Members are a highly diverse ... government health programs, editorial, and business entrepreneurship. The Board also ... heterosexual and gay Black men and women, some living with ...
... Broad Political Endorsements, Business, and Press Join Effort to ... again, the National Bipolar Foundation and the MedicAlert Foundation receive ... now being widely accepted as a preventive health care measure ... proclamation of endorsement via Federal Express Priority Mail from the ...
... have found evidence of a statistically significant survival ... receptor (ER)-positive tumors had high levels of phosphorylation ... a brief communication published online November 25 in ... . Approximately 50% of breast carcinomas are ...
... pressure? This simple question has been the focus of ... High Blood Pressure in Mice & Men, Does stress increase ... of intense research for many years. Now new research ... novel gene, phosducin, and the blood pressure response to stress ...
... Rituximab, already used to fight rheumatoid arthritis, could help ... (HealthDay News) -- A drug commonly used to treat ... promise in helping patients newly diagnosed with type 1 ... producing some of their own insulin, even though the ...
Cached Medicine News:Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 4Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... both 96- and 384-well plates and ... Washer. As a self contained and ... full control of precise fluidic delivery ... simple squeeze bottle to the full ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: